These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37018790)

  • 1. Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII).
    Oliveira GBF; Neves PDMM; Oliveira HA; Catarino DGM; Alves LBO; Cavalcanti AB; Rosa RG; Veiga VC; Azevedo LCP; Berwanger O; Lopes RD; Avezum Á
    Arq Bras Cardiol; 2023 Mar; 120(3):e20220431. PubMed ID: 37018790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial.
    Avezum Á; Oliveira Junior HA; Neves PDMM; Alves LBO; Cavalcanti AB; Rosa RG; Veiga VC; Azevedo LCP; Zimmermann SL; Silvestre OM; Seabra Prudente RC; Morales Kormann AP; Moreira FR; Boszczowski I; de Brito Sobrinho E; da Silva E Souza A; Seligman R; de Souza Paolino B; Razuk A; Diogenes de Magalhaes Feitosa A; Monteiro Belmonte PL; Freitas das Neves Gonçalves P; Hernandes ME; Fagundes AL; Sarmet Esteves JM; Tognon AP; Eikelboom J; Berwanger O; Lopes RD; Oliveira GBF;
    EClinicalMedicine; 2023 Jun; 60():102004. PubMed ID: 37223666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Ramacciotti E; Damini LP; Bronhara B; Cavalcanti AB; Rosa RG; Azevedo LCP; Veiga VC; Machado FR; Ritt LE; Martins PA; Alexander JH; Avezum A; Berwanger O;
    Am Heart J; 2021 Aug; 238():1-11. PubMed ID: 33891907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
    Piazza G; Spyropoulos AC; Hsia J; Goldin M; Towner WJ; Go AS; Bull TM; Weng S; Lipardi C; Barnathan ES; Bonaca MP;
    Circulation; 2023 Jun; 147(25):1891-1901. PubMed ID: 37154020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
    Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
    Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
    Capell WH; Barnathan ES; Piazza G; Spyropoulos AC; Hsia J; Bull S; Lipardi C; Sugarmann C; Suh E; Rao JP; Hiatt WR; Bonaca MP
    Am Heart J; 2021 May; 235():12-23. PubMed ID: 33577800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and Design of the COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V) Randomized Clinical Trial: Hydroxychloroquine vs. Placebo in Non-Hospitalized Patients.
    Oliveira Junior HA; Ferri CP; Boszczowski I; Oliveira GBF; Cavalcanti AB; Rosa RG; Lopes RD; Azevedo LCP; Veiga VC; Berwanger O; Avezum Á
    Arq Bras Cardiol; 2022 Feb; 118(2):378-387. PubMed ID: 35262569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial.
    Rauch-Kröhnert U; Puccini M; Placzek M; Beyer-Westendorf J; Jakobs K; Friebel J; Hein S; Seidel M; Pieske B; Massberg S; Witzenrath M; Zeiher A; Friede T; Anker SD; Landmesser U
    Clin Res Cardiol; 2023 Nov; 112(11):1620-1638. PubMed ID: 37407731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O;
    Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.